Abstract P3-04-14: Prognostic impact of Her2 and hormone receptor expression in inflammatory breast cancer: A SEER database analysis

Abstract

Abstract INTRODUCTION: Inflammatory breast cancer (IBC) is known to be one of the most aggressive forms of breast cancer. Patients with IBC generally present with early metastases and are frequently resistant to conventional chemotherapies. By using the SEER database, we explored the clinical relevance of Her2 and hormone receptor (HR) expression in IBC tumors and the possible impact it may have on management. METHODS: Data for patients with IBC was extracted from the Surveillance, Epidemiology, and End Results (SEER 18) database from 2010 to 2011. A sub-analysis with the available receptor status data for the same period was analyzed using CanSurv survival software. The Actuarial method was used to construct survival curves according to the following receptor variables; Her2+/HR+, Her2+/HR-, Her2-/HR+, and triple negative IBC groups. Demographic data including race and age was also extracted. RESULTS: Of 354 cases of IBC reported, 5% (n=18) of the tumors were Her2+/HR+, 7.9% (n=28) Her2+/HR-, 15.3% (n=54) Her2-/HR+, and 12.4% (n=44) triple negative. Highest 1 year survival rates were seen in those patients with Her2-/HR+ tumors at >95% while Her2+/HR+ had the lowest 1 yr survival rates at 65%. Caucasian patients above 30 years represented the highest racial group at approximately 70% (n=105). Analysis of this subgroup showed 38% (n=40) of these patients having HER2-/HR+. Despite more than 75% (n=33) of these patients presenting with advanced disease, the 1 year survival remained highest among all the receptor combinations analyzed. This observation held true across all racial groups even with those population numbers for IBC being less. CONCLUSION: The Her2-/HR+ receptor combination group showed the greatest 1 year relative survival when compared to the other groups. These results suggest that HR expression in the absence of Her2 is associated with an increased survival. This can play in a role in the management of IBC by incorporating hormonal therapy into the treatment protocols for patients with IBC to possibly improve survival. Citation Format: Anna Maria Affan, Babu P Mohan, Kali Praveena Iruku, Keyvan Ravakhah. Prognostic impact of Her2 and hormone receptor expression in inflammatory breast cancer: A SEER database analysis [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-04-14.